Using and interpreting cost-effectiveness acceptability curves: an example using data from a trial of management strategies for atrial fibrillation
<p>Abstract</p> <p>Background</p> <p>The cost-effectiveness acceptability curve (CEAC) is a method for summarizing the uncertainty in estimates of cost-effectiveness. The CEAC, derived from the joint distribution of costs and effects, illustrates the (Bayesian) probabil...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2006-04-01
|
| Series: | BMC Health Services Research |
| Online Access: | http://www.biomedcentral.com/1472-6963/6/52 |
| _version_ | 1819124524323438592 |
|---|---|
| author | Levy Adrian R Marshall Deborah A Fenwick Elisabeth Nichol Graham |
| author_facet | Levy Adrian R Marshall Deborah A Fenwick Elisabeth Nichol Graham |
| author_sort | Levy Adrian R |
| collection | DOAJ |
| description | <p>Abstract</p> <p>Background</p> <p>The cost-effectiveness acceptability curve (CEAC) is a method for summarizing the uncertainty in estimates of cost-effectiveness. The CEAC, derived from the joint distribution of costs and effects, illustrates the (Bayesian) probability that the data are consistent with a true cost-effectiveness ratio falling below a specified ceiling ratio. The objective of the paper is to illustrate how to construct and interpret a CEAC.</p> <p>Methods</p> <p>A retrospective cost-effectiveness analysis of the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) randomized controlled trial with 4060 patients followed for 3.5 years. The target population was patients with atrial fibrillation who were 65 years of age or had other risk factors for stroke or death similar to those enrolled in AFFIRM. The intervention involved the management of patients with atrial fibrillation with antiarrhythmic drugs (rhythm-control) compared with drugs that control heart rate (rate-control). Measurements of mean survival, mean costs and incremental cost-effectiveness were made. The uncertainty surrounding the estimates of cost-effectiveness was illustrated through a cost-effectiveness acceptability curve.</p> <p>Results</p> <p>The base case point estimate for the difference in effects and costs between rate and rhythm-control is 0.08 years (95% CI: -0.1 years to 0.24 years) and -US$5,077 (95% CI: -$1,100 to -$11,006). The CEAC shows that the decision uncertainty surrounding the adoption of rate-control strategies is less than 1.7% regardless of the maximum acceptable ceiling ratio. Thus, there is very little uncertainty surrounding the decision to adopt rate-control compared to rhythm-control for patients with atrial fibrillation from a resource point of view.</p> <p>Conclusion</p> <p>The CEAC is straightforward to calculate, construct and interpret. The CEAC is useful to a decision maker faced with the choice of whether or not to adopt a technology because it provides a measure of the decision uncertainty surrounding the choice.</p> |
| first_indexed | 2024-12-22T07:25:37Z |
| format | Article |
| id | doaj.art-2e3d791573374e4db2475c65dd9aa9fa |
| institution | Directory Open Access Journal |
| issn | 1472-6963 |
| language | English |
| last_indexed | 2024-12-22T07:25:37Z |
| publishDate | 2006-04-01 |
| publisher | BMC |
| record_format | Article |
| series | BMC Health Services Research |
| spelling | doaj.art-2e3d791573374e4db2475c65dd9aa9fa2022-12-21T18:34:08ZengBMCBMC Health Services Research1472-69632006-04-01615210.1186/1472-6963-6-52Using and interpreting cost-effectiveness acceptability curves: an example using data from a trial of management strategies for atrial fibrillationLevy Adrian RMarshall Deborah AFenwick ElisabethNichol Graham<p>Abstract</p> <p>Background</p> <p>The cost-effectiveness acceptability curve (CEAC) is a method for summarizing the uncertainty in estimates of cost-effectiveness. The CEAC, derived from the joint distribution of costs and effects, illustrates the (Bayesian) probability that the data are consistent with a true cost-effectiveness ratio falling below a specified ceiling ratio. The objective of the paper is to illustrate how to construct and interpret a CEAC.</p> <p>Methods</p> <p>A retrospective cost-effectiveness analysis of the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) randomized controlled trial with 4060 patients followed for 3.5 years. The target population was patients with atrial fibrillation who were 65 years of age or had other risk factors for stroke or death similar to those enrolled in AFFIRM. The intervention involved the management of patients with atrial fibrillation with antiarrhythmic drugs (rhythm-control) compared with drugs that control heart rate (rate-control). Measurements of mean survival, mean costs and incremental cost-effectiveness were made. The uncertainty surrounding the estimates of cost-effectiveness was illustrated through a cost-effectiveness acceptability curve.</p> <p>Results</p> <p>The base case point estimate for the difference in effects and costs between rate and rhythm-control is 0.08 years (95% CI: -0.1 years to 0.24 years) and -US$5,077 (95% CI: -$1,100 to -$11,006). The CEAC shows that the decision uncertainty surrounding the adoption of rate-control strategies is less than 1.7% regardless of the maximum acceptable ceiling ratio. Thus, there is very little uncertainty surrounding the decision to adopt rate-control compared to rhythm-control for patients with atrial fibrillation from a resource point of view.</p> <p>Conclusion</p> <p>The CEAC is straightforward to calculate, construct and interpret. The CEAC is useful to a decision maker faced with the choice of whether or not to adopt a technology because it provides a measure of the decision uncertainty surrounding the choice.</p>http://www.biomedcentral.com/1472-6963/6/52 |
| spellingShingle | Levy Adrian R Marshall Deborah A Fenwick Elisabeth Nichol Graham Using and interpreting cost-effectiveness acceptability curves: an example using data from a trial of management strategies for atrial fibrillation BMC Health Services Research |
| title | Using and interpreting cost-effectiveness acceptability curves: an example using data from a trial of management strategies for atrial fibrillation |
| title_full | Using and interpreting cost-effectiveness acceptability curves: an example using data from a trial of management strategies for atrial fibrillation |
| title_fullStr | Using and interpreting cost-effectiveness acceptability curves: an example using data from a trial of management strategies for atrial fibrillation |
| title_full_unstemmed | Using and interpreting cost-effectiveness acceptability curves: an example using data from a trial of management strategies for atrial fibrillation |
| title_short | Using and interpreting cost-effectiveness acceptability curves: an example using data from a trial of management strategies for atrial fibrillation |
| title_sort | using and interpreting cost effectiveness acceptability curves an example using data from a trial of management strategies for atrial fibrillation |
| url | http://www.biomedcentral.com/1472-6963/6/52 |
| work_keys_str_mv | AT levyadrianr usingandinterpretingcosteffectivenessacceptabilitycurvesanexampleusingdatafromatrialofmanagementstrategiesforatrialfibrillation AT marshalldeboraha usingandinterpretingcosteffectivenessacceptabilitycurvesanexampleusingdatafromatrialofmanagementstrategiesforatrialfibrillation AT fenwickelisabeth usingandinterpretingcosteffectivenessacceptabilitycurvesanexampleusingdatafromatrialofmanagementstrategiesforatrialfibrillation AT nicholgraham usingandinterpretingcosteffectivenessacceptabilitycurvesanexampleusingdatafromatrialofmanagementstrategiesforatrialfibrillation |